Louisiana to receive $6M in EpiPen settlement
BATON ROUGE- Louisiana has joined a multi-state settlement with Mylan Inc. that resolves allegations the drug manufacturer knowingly overcharged taxpayers for EpiPen and EpiPen Jr. dispensed to Medicaid beneficiaries.
The announcement came from Attorney General Jeff Landry’s office.
Mylan will pay $465 million to the federal government and the states, Louisiana’s portion is $6,922,152.05. Landry said the money will go towards replenishing the state’s Medicaid program.
Mylan allegedly submitted false statements to the Centers for Medicare and Medicaid Services that incorrectly classified EpiPen as a “non-innovator multiple source” drug, as opposed to a “single source” or “innovator multiple source” drug from July 29, 2010 to March 31 of this year.
As a result, Mylan submitted or caused false statements to be submitted to CMS and/or the states relating to EpiPen for Medicaid rebate purposes and underpaid its EpiPen rebates to the state Medicaid programs.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Local landscaper helps dying woman by cutting yards for free
DOTD updates LA 1 repairs after truck collision this week
Top players, amateurs flock to 30th annual Cajun Classic Wheelchair Tennis Tournament
Hundreds of prom dresses donated to high school girls
2 Make a Difference: Dash for Deaf Kids